Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. It operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. The company offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. It also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, the company provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. It provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is headquartered in Indianapolis, Indiana.

Elevance Health Inc.

Elevra Lithium ( ($AU:ELV) ) has shared an announcement. On June 22, 2026, Elevra Lithium Limited filed a Form 6-K in the United States, mainly to ...

Elevra Lithium Directors Boost Stakes in June 2026 Share Purchase Plan

Insiders have been trading these 5 stocks: (($CAVA)), (($AAOI)), (($ELV)), (($INOD)) and (($ABAT)). Here is a breakdown of their recent trades and ...

CAVA, Applied Optoelectronics, Elevance, Innodata, American Battery Shock

In a report released today, from Macquarie upgraded Elevra Lithium to a Buy, with a price target of A$13.50. Currently, the analyst consensus on El...

Positive Report for Elevra Lithium (SYAXF) from Macquarie

Insiders have been trading these 5 stocks: (($USAR)), (($CNC)), (($ONON)), (($ELV)) and (($AMPX)). Here is a breakdown of their recent trades and t...

USA Rare Earth, Centene, On, Elevance, Amprius Insider Shock

The latest update is out from Enliven Therapeutics ( ($ELVN) ). On June 11, 2026, Enliven Therapeutics priced an upsized underwritten public offeri...

Enliven Therapeutics Prices Upsized Public Equity Offering

Enliven Therapeutics stock was up on news of an upsized public offering.


Why Is Enliven Therapeutics Stock (ELVN) Up Today?

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Enliven Therapeutics (ELVN), Invivyd (IVVD) and Damo...

Analysts’ Top Healthcare Picks: Enliven Therapeutics (ELVN), Invivyd (IVVD)

Elvictor Group ( ($ELVG) ) just unveiled an announcement. On June 11, 2026, Elvictor Group appointed 26-year-old technologist Theocharis Vasilakis ...

Elvictor Group Names New CTO to Drive AI Transformation

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY). Enlive...

Analysts Offer Insights on Healthcare Companies: Enliven Therapeutics (ELVN) and Oncolytics Biotech (ONCY)

Elvictor Group ( ($ELVG) ) has shared an update. On June 11, 2026, Elvictor Group, Inc. removed Christodoulos Tzoutzakis from his roles as Chief Op...

Elvictor Group Removes Chief Operating and Technology Officer

Enliven Therapeutics ( ($ELVN) ) just unveiled an announcement. Enliven Therapeutics, Inc. held its Annual Meeting of Stockholders on June 9, 2026,...

Enliven Therapeutics Expands Authorized Shares After Stockholder Vote

Elevance Health ( ($ELV) ) has shared an announcement. Elevance Health told investors and analysts this week that it is reaffirming its full-year 2...

Elevance Health Reaffirms 2026 Earnings and Cost Targets

Bernstein analyst Lance Wilkes maintained a Buy rating on Elevance Health today and set a price target of $424.00. According to TipRanks, Wilkes is...

Bernstein Sticks to Its Buy Rating for Elevance Health (ELV)

Stocks ended the week sharply lower as a stronger-than-expected May jobs report pushed bond yields higher and hit the market’s biggest winners. The...

The Week That Was, The Week Ahead: Macro and Markets, June 7

Elevra Lithium ( ($AU:ELV) ) has issued an update. S&P Dow Jones Indices has announced its June 2026 quarterly rebalance of the S&P/ASX indices, wi...

Index Shake-Up Puts Elevra Lithium Into S&P/ASX 200 as S&P Dow Jones Rebalances Benchmarks

Elevra Lithium ( ($AU:ELV) ) has issued an announcement. Elevra Lithium Limited has disclosed a change in director Lucas Dow’s interests, with Dow ...

Elevra Lithium director boosts stake via share purchase plan

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. Elevra Lithium director Laurie Lefcourt has increased his direct holding in the company, purc...

Elevra Lithium Director Boosts Stake via Share Purchase Plan

Elevra Lithium ( ($AU:ELV) ) has provided an announcement. Elevra Lithium Limited has applied to the ASX for quotation of 1,275,668 new ordinary fu...

Elevra Lithium Seeks ASX Quotation for New Share Issue

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Elevance Health (ELV) and Indivior (INDV) with bulli...

Analysts Are Bullish on Top Healthcare Stocks: Elevance Health (ELV), Indivior (INDV)

Bank of America Securities analyst Kevin Fischbeck maintained a Buy rating on Elevance Health today and set a price target of $460.00. According to...

Bank of America Securities Remains a Buy on Elevance Health (ELV)

In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Enliven Therapeutics, with a price target of $62.00. Accor...

Mizuho Securities Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)

This article highlights three ETFs rated by TipRanks’ AI analyst as Outperform and carrying at least 10% upside potential from Wall Street analysts...

AI Analyst Picks 3 Best ETFs with 10%+ Upside, 6/1/2026

Macquarie analyst maintained a Hold rating on Elevra Lithium today and set a price target of A$13.50. Currently, the analyst consensus on Elevra Li...

Macquarie Reaffirms Their Hold Rating on Elevra Lithium (SYAXF)

Elevra Lithium ( ($AU:ELV) ) just unveiled an update. State Street Corporation, through its various asset management and custody subsidiaries, has ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ELV	$394.82	+1.63%	1.17M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ELV	$394.82	+1.6%	1.17M
3
4
5
6

ELV

ELV

Get Elevance Health Inc. Data in Excel

Get Elevance Health Inc. Data in Excel